{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:55:12Z","timestamp":1790034912932,"version":"4.0.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"20","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Targeting cell surface receptors with cytotoxins or immunotoxins provides a unique opportunity for tumor therapy. Here, we show the efficacy of the combination therapy of gemcitabine with an interleukin-4 (IL-4) cytotoxin composed of IL-4 and truncated Pseudomonas exotoxin in animal models of pancreatic ductal adenocarcinoma (PDA). We have observed that 42 of 70 (60%) tumor samples from patients with PDA express moderate- to high-density surface IL-4 receptor (IL-4R), whereas normal pancreatic samples express no or low-density IL-4R. IL-4 cytotoxin was specifically and highly cytotoxic [50% protein synthesis inhibition (IC50) ranging from &amp;gt;0.1 to 13 ng\/mL] to six of eight pancreatic cancer cell lines, whereas no cytotoxicity (IC50 &amp;gt;1,000 ng\/mL) was observed in normal human pancreatic duct epithelium cells, fibroblasts, and human umbilical vein endothelial cells (HUVEC). We also showed that IL-4 cytotoxin in combination with gemcitabine exhibited synergistic antitumor activity in vitro. To confirm synergistic antitumor activity in vivo and monitor precise real-time disease progression, we used a novel metastatic and orthotopic mouse model using green fluorescent protein\u2013transfected cancer cells and whole-body imaging system. The combination of both agents caused complete eradication of tumors in 40% of nude mice with small established PDA tumors. In addition, combined treatment significantly prolonged the survival of nude mice bearing day 14 advanced distant metastatic PDA tumors. Similar results were observed in mice xenografted with PDA obtained from a patient undergoing surgical resection. These results indicate that IL-4 cytotoxin combined with gemcitabine may provide effective therapy for the treatment of patients with PDA. [Cancer Res 2007;67(20):9903\u201312]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4558","type":"journal-article","created":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T21:39:01Z","timestamp":1192657141000},"page":"9903-9912","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1158","volume":"67","author":[{"given":"Takeshi","family":"Shimamura","sequence":"first","affiliation":[{"name":"1Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Royal","sequence":"additional","affiliation":[{"name":"2Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitomu","family":"Kioi","sequence":"additional","affiliation":[{"name":"1Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"3Gastroenterology Division, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed R.","family":"Husain","sequence":"additional","affiliation":[{"name":"1Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj K.","family":"Puri","sequence":"additional","affiliation":[{"name":"1Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,10,17]]},"reference":[{"key":"2022061623221200400_B1","doi-asserted-by":"crossref","unstructured":"Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg\u20081999; 189: 1\u20137.","DOI":"10.1016\/S1072-7515(99)00075-7"},{"key":"2022061623221200400_B2","doi-asserted-by":"crossref","unstructured":"Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol\u20082003; 21: 3402\u20138.","DOI":"10.1200\/JCO.2003.09.140"},{"key":"2022061623221200400_B3","doi-asserted-by":"crossref","unstructured":"Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol\u20081997; 15: 2403\u201313.","DOI":"10.1200\/JCO.1997.15.6.2403"},{"key":"2022061623221200400_B4","unstructured":"Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res\u20082000; 60: 2926\u201335."},{"key":"2022061623221200400_B5","doi-asserted-by":"crossref","unstructured":"Yokoi K, Sasaki T, Bucana CD, et al. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res\u20082005; 65: 10371\u201380.","DOI":"10.1158\/0008-5472.CAN-05-1698"},{"key":"2022061623221200400_B6","doi-asserted-by":"crossref","unstructured":"Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest\u20082003; 111: 1287\u201395.","DOI":"10.1172\/JCI200317929"},{"key":"2022061623221200400_B7","doi-asserted-by":"crossref","unstructured":"Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-\u03baB activity by I\u03baB \u03b1M suppresses tumorigenesis. Oncogene\u20082003; 22: 1365\u201370.","DOI":"10.1038\/sj.onc.1206323"},{"key":"2022061623221200400_B8","doi-asserted-by":"crossref","unstructured":"Moore MJ, Goldstein J, Hamm A, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement); 2005:1.","DOI":"10.1200\/jco.2005.23.16_suppl.1"},{"key":"2022061623221200400_B9","doi-asserted-by":"crossref","unstructured":"Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer\u20082006; 6: 559\u201365.","DOI":"10.1038\/nrc1891"},{"key":"2022061623221200400_B10","unstructured":"Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res\u20082000; 6: 2157\u201365."},{"key":"2022061623221200400_B11","doi-asserted-by":"crossref","unstructured":"Weber F, Asher A, Bucholz R, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol\u20082003; 64: 125\u201337.","DOI":"10.1007\/BF02700027"},{"key":"2022061623221200400_B12","doi-asserted-by":"crossref","unstructured":"Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat\u20082006; 5: 239\u201350.","DOI":"10.1177\/153303460600500307"},{"key":"2022061623221200400_B13","doi-asserted-by":"crossref","unstructured":"Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol\u20082005; 23: 6719\u201329.","DOI":"10.1200\/JCO.2005.11.437"},{"key":"2022061623221200400_B14","doi-asserted-by":"crossref","unstructured":"Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol\u20081999; 17: 701\u201338.","DOI":"10.1146\/annurev.immunol.17.1.701"},{"key":"2022061623221200400_B15","unstructured":"Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res\u20081992; 52: 275\u20139."},{"key":"2022061623221200400_B16","unstructured":"Topp MS, Papadimitriou CA, Eitelbach F, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res\u20081995; 55: 2173\u20136."},{"key":"2022061623221200400_B17","doi-asserted-by":"crossref","unstructured":"Stadler WM, Rybak ME, Vogelzang NJ. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer\u20081995; 76: 1629\u201333.","DOI":"10.1002\/1097-0142(19951101)76:9<1629::AID-CNCR2820760920>3.0.CO;2-Q"},{"key":"2022061623221200400_B18","doi-asserted-by":"crossref","unstructured":"Husain SR, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med\u20081999; 5: 817\u201322.","DOI":"10.1038\/10541"},{"key":"2022061623221200400_B19","unstructured":"Kawakami K, Kawakami M, Husain SR, Puri RK. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res\u20082002; 62: 3575\u201380."},{"key":"2022061623221200400_B20","unstructured":"Kawakami M, Kawakami K, Stepensky VA, et al. Interleukin-4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin Cancer Res\u20082002; 8: 3503\u201311."},{"key":"2022061623221200400_B21","doi-asserted-by":"crossref","unstructured":"Kawakami M, Kawakami K, Puri RK. Interleukin-4 Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol\u20082003; 65: 15\u201325.","DOI":"10.1023\/A:1026294416718"},{"key":"2022061623221200400_B22","doi-asserted-by":"crossref","unstructured":"Kawakami K, Kawakami M, Puri RK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol\u20082001; 21: 299\u2013310.","DOI":"10.1615\/CritRevImmunol.v21.i1-3.200"},{"key":"2022061623221200400_B23","doi-asserted-by":"crossref","unstructured":"Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci U S A\u20081994; 91: 6889\u201393.","DOI":"10.1073\/pnas.91.15.6889"},{"key":"2022061623221200400_B24","doi-asserted-by":"crossref","unstructured":"Kioi M, Takahashi S, Kawakami M, Kawakami K, Kreitman RJ, Puri RK. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. Cancer Res\u20082005; 65: 8388\u201396.","DOI":"10.1158\/0008-5472.CAN-05-1043"},{"key":"2022061623221200400_B25","doi-asserted-by":"crossref","unstructured":"Garland L, Gitlitz B, Ebbinghaus S, et al. Phase I trial of intravenous IL-4 Pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother\u20082005; 28: 376\u201381.","DOI":"10.1097\/01.cji.0000162782.86008.mL"},{"key":"2022061623221200400_B26","doi-asserted-by":"crossref","unstructured":"Rainov NG, Heidecke V. Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001). J Neurooncol\u20082004; 66: 197\u2013201.","DOI":"10.1023\/B:NEON.0000013478.27604.01"},{"key":"2022061623221200400_B27","doi-asserted-by":"crossref","unstructured":"Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer\u20082005; 10: 796\u2013806.","DOI":"10.1038\/nrc1717"},{"key":"2022061623221200400_B28","unstructured":"Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol\u20081996; 148: 1763\u201370."},{"key":"2022061623221200400_B29","doi-asserted-by":"crossref","unstructured":"Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer\u20081994; 58: 574\u201381.","DOI":"10.1002\/ijc.2910580421"},{"key":"2022061623221200400_B30","doi-asserted-by":"crossref","unstructured":"Chou TC, Motzer R, Tong Y, Bosl G. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst\u20081994; 86: 1517\u201324.","DOI":"10.1093\/jnci\/86.20.1517"},{"key":"2022061623221200400_B31","doi-asserted-by":"crossref","unstructured":"Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun\u20081997; 238: 90\u20134.","DOI":"10.1006\/bbrc.1997.7248"},{"key":"2022061623221200400_B32","unstructured":"Bouvet M, Wang J, Nardin SR, et al. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res\u20082002; 62: 1534\u201340."},{"key":"2022061623221200400_B33","doi-asserted-by":"crossref","unstructured":"Abbruzzese JL. Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. Semin Oncol\u20082002; 29: 2\u20138.","DOI":"10.1053\/sonc.2002.37382"},{"key":"2022061623221200400_B34","doi-asserted-by":"crossref","unstructured":"Symon Z, Davis M, McGinn CJ, Zalupski MM, Lawrence TS. Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys\u20082002; 53: 140\u20135.","DOI":"10.1016\/S0360-3016(01)02790-0"},{"key":"2022061623221200400_B35","doi-asserted-by":"crossref","unstructured":"Bocci G, Fioravanti A, Orlandi P, et al. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer\u20082005; 93: 319\u201330.","DOI":"10.1038\/sj.bjc.6602720"},{"key":"2022061623221200400_B36","doi-asserted-by":"crossref","unstructured":"Pratesi G, Petrangolini G, Tortoreto M, et al. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res\u20082005; 65: 6388\u201393.","DOI":"10.1158\/0008-5472.CAN-05-0602"},{"key":"2022061623221200400_B37","doi-asserted-by":"crossref","unstructured":"Chun PY, Feng FY, Scheurer AM, et al. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res\u20082006; 66: 981\u20138.","DOI":"10.1158\/0008-5472.CAN-05-2665"},{"key":"2022061623221200400_B38","doi-asserted-by":"crossref","unstructured":"O'Connor R, Liu C, Ferris CA, et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood\u20081995; 86: 4286\u201394.","DOI":"10.1182\/blood.V86.11.4286.bloodjournal86114286"},{"key":"2022061623221200400_B39","doi-asserted-by":"crossref","unstructured":"Kim CN, Bhalla K, Kreitman RJ, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leuk Res\u20081999; 23: 527\u201338.","DOI":"10.1016\/S0145-2126(99)00039-9"},{"key":"2022061623221200400_B40","doi-asserted-by":"crossref","unstructured":"Polito L, Bolognesi A, Tazzari PL, et al. The conjugate Rituximab\/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia\u20082004; 18: 1215\u201322.","DOI":"10.1038\/sj.leu.2403378"},{"key":"2022061623221200400_B41","doi-asserted-by":"crossref","unstructured":"Gilbert JA, Lloyd RV, Ames MM. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med\u20082005; 353: 209\u201310.","DOI":"10.1056\/NEJM200507143530219"},{"key":"2022061623221200400_B42","unstructured":"Morgan A. Recently approved antineoplastic agents. Highlights Oncol Pract\u20081996; 14: 74\u20139."},{"key":"2022061623221200400_B43","unstructured":"Husain SR, Kawakami K, Kawakami M, Puri RK. Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models. Mol Cancer Ther\u20082003; 2: 245\u201354."},{"key":"2022061623221200400_B44","doi-asserted-by":"crossref","unstructured":"Manzotti C, Audisio RA, Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis\u20081993; 11: 5\u201314.","DOI":"10.1007\/BF00880061"},{"key":"2022061623221200400_B45","unstructured":"Strome SE, Kawakami K, Alejandro D, et al. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. Clin Cancer Res\u20082002; 8: 281\u20136."},{"key":"2022061623221200400_B46","doi-asserted-by":"crossref","unstructured":"Bouvet M, Spernyak J, Katz MH, et al. High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. Cancer Res\u20082005; 65: 9829\u201333.","DOI":"10.1158\/0008-5472.CAN-05-1548"},{"key":"2022061623221200400_B47","doi-asserted-by":"crossref","unstructured":"Saur D, Seidler B, Schneider G, et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology\u20082005; 129: 1237\u201350.","DOI":"10.1053\/j.gastro.2005.06.056"},{"key":"2022061623221200400_B48","doi-asserted-by":"crossref","unstructured":"Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res\u20082003; 113: 151\u201360.","DOI":"10.1016\/S0022-4804(03)00234-8"},{"key":"2022061623221200400_B49","doi-asserted-by":"crossref","unstructured":"Zhang X, Galardi E, Duquette M, Lawler J, Parangi S. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res\u20082005; 11: 5622\u201330.","DOI":"10.1158\/1078-0432.CCR-05-0459"},{"key":"2022061623221200400_B50","unstructured":"Puri RK, Hoon DS, Leland P, et al. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res\u20081996; 56: 5631\u20137."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/20\/9903\/2575764\/9903.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/20\/9903\/2575764\/9903.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T03:02:44Z","timestamp":1655434964000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/20\/9903\/533742\/Interleukin-4-Cytotoxin-Therapy-Synergizes-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,15]]},"references-count":50,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2007,10,17]]},"published-print":{"date-parts":[[2007,10,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4558","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,15]]}}}